Astrotech Corporation
5914 W. Courtyard Drive
Suite 340
Austin
Texas
78730
United States
Tel: 512-485-9530
Website: http://www.astrotechcorp.com/
About Astrotech Corporation
Astrotech Corporation is an Austin, TX based technology company that identifies and commercializes emerging technologies through its closely held subsidiaries. Management sources investment opportunities from various government laboratories, agencies, universities, and corporations, as well as through its own internal research.YEAR FOUNDED:
1984
LEADERSHIP:
CEO: Thomas B. Pickens, III
CFO: Eric N. Stober
COO: Raj Mellacheruvu
JOBS:
Please click here for Astrotech job opportunitites.
FOLLOW ASTROTECH:
Tweets by Astrotech
39 articles about Astrotech Corporation
-
Astrotech Announces Date for Fiscal Year 2022 Annual Meeting and Deadlines for Stockholder Proposals
8/24/2022
Astrotech Corporation (Nasdaq: ASTC) (the “Company”) announced its plans to hold its fiscal year 2022 annual meeting of stockholders (the “2022 Annual Meeting”) on Tuesday, November 15, 2022.
-
Astrotech Appoints Jim Becker to Board of Directors
6/23/2022
Astrotech Corporation (Nasdaq: ASTC) announced today that it has appointed Jim Becker to its Board of Directors.
-
Astrotech Subsidiary and Cleveland Clinic Expand Breath Analysis Study to Detect Multiple Diseases
6/23/2022
Astrotech Corporation’s (NASDAQ: ASTC) subsidiary, BreathTech Corporation, announced today that it has amended its Joint Development and Option Agreement with Cleveland Clinic to include additional areas of focus.
-
Astrotech Reports Third Quarter of Fiscal Year 2022 Financial Results
5/12/2022
Astrotech Corporation (Nasdaq: ASTC) (the “Company” or “Astrotech”) reported its financial results for the third quarter of fiscal year 2022, which ended March 31, 2022.
-
Astrotech Subsidiary BreathTech Hires Dr. Karim Sirgi as Its Chief Science Officer
2/2/2022
Astrotech Corporation (Nasdaq: ASTC) has hired Dr. Karim Sirgi, MD, MBA and FCAP as the Chief Science Officer of subsidiary BreathTech Corporation in preparation of human trials with Cleveland Clinic for its BreathTest-1000™ to help in the battle against COVID-19 and its variants.
-
Astrotech Begins Search for Strategic Acquisitions
11/17/2021
Astrotech Corporation now intends to actively pursue strategic and accretive acquisition opportunities.
-
Astrotech Reports First Quarter of Fiscal Year 2022 Financial Results
11/12/2021
Astrotech Corporation (Nasdaq: ASTC) reported its financial results for the first quarter of fiscal year 2022, which ended September 30, 2021.
-
Astrotech Reports Fiscal Year 2021 Financial Results
9/20/2021
Astrotech Corporation (Nasdaq: ASTC) reported its financial results for the fiscal year ended June 30, 2021.
-
Astrotech Announces Closing of $37.3 Million Bought Deal Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares
4/12/2021
Astrotech Corporation (NASDAQ: ASTC), announced today the closing of its previously announced underwritten public offering of 24,885,828 shares of its common stock, which included 3,245,977 shares sold pursuant to the full exercise of the underwriter’s option to purchase additional shares, at a price to the public of $1.50 per share, less underwriting discounts and commissions.
-
Astrotech Increases Previously Announced Bought Deal Offering of Common Stock to $32.5 Million
4/8/2021
Astrotech Corporation, announced that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 21,639,851 shares of common stock of the Company at a price to the public of $1.50 per share, less underwriting discounts and commissions.
-
Astrotech Announces $10 Million Bought Deal Offering of Common Stock
4/7/2021
Astrotech Corporation (NASDAQ: ASTC), today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co. under which the underwriter has agreed to purchase on a firm commitment basis 6,666,667 shares of common stock (or common stock equivalents in lieu thereof) of the Company at a price to the public of $1.50 per share (or common stock equivalent), less underwriting discounts and commissions.
-
Astrotech Engages Sanmina to Scale Manufacturing
3/30/2021
Astrotech Corporation announced that its Astrotech Technologies, Inc. subsidiary has entered into an agreement with Sanmina Corporation to manufacture its mass spectrometry products.
-
Astrotech Reports Second Quarter of Fiscal Year 2021 Financial Results
2/16/2021
Astrotech Corporation (NASDAQ: ASTC) reported its financial results for the second quarter of fiscal year 2021, which ended December 31, 2020. Since the beginning of the quarter, we successfully raised a total of $37.0 million in gross proceeds, strengthening our balance sheet for our future growth and expansion of our business.
-
Astrotech Reports First Quarter of Fiscal Year 2021 Financial Results
11/12/2020
Astrotech Corporation reported its financial results for the first quarter of fiscal year 2021, which ended September 30, 2020.
-
Astrotech Announces $6.2 Million Registered Direct Offering Priced At-the-Market
10/29/2020
Astrotech Corporation (NASDAQ: ASTC), today announced that it has entered into definitive agreements with several institutional investors for the purchase and sale of 2,887,906 shares of Astrotech's common stock, at a purchase price of $2.15 per share, in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about October 30, 2020, subject to the satisf
-
Astrotech Reports Fiscal Year 2020 Financial Results
9/8/2020
Fiscal year 2020 has been a pivotal year for Astrotech Corporation. We had the first sales of our TRACER 1000™ explosives trace detector, we completed a number of successful field trials including a live screening with the U.S. Transportation Security Administration at Miami International Airport, and we signed a key contract with a global shipping and logistics company.
-
Astrotech’s BreathTest-1000 Confirmed to Detect Lung Disease Metabolites at Parts Per Billion
3/27/2020
Astrotech Corporation [NASDAQ: ASTC] announced that the BreathTest-1000™ lung disease screening device that is under development detects a known metabolite that is associated with lung diseases at very low parts per billion (ppb) concentrations. On March 25, the Company announced that it is working on developing the BreathTest-1000™ to detect volatile organic compound metabolites present in lung diseases such as the Coron
-
Astrotech Announces Closing of $1.77 Million Registered Direct Offering Priced At-the-Market
3/26/2020
Astrotech Corporation, announced that it has closed its previously announced registered direct offering priced at-the-market of 354,000 shares of its common stock at a price of $5.00 per share for aggregate gross proceeds of $1.77 million.
-
Astrotech Developing Screening Instrument for Lung Diseases Including COVID-19/Coronavirus & Pneumonia
3/25/2020
Astrotech Corporation [NASDAQ: ASTC] today announced that the BreathTest-1000™ is under development to screen for volatile organic compound (VOC) metabolites found in a person’s breath that could indicate they may have an infection, including Coronavirus Disease 2019 (“COVID-19”) or the resulting disease, pneumonia. The Company believes that its unique mass spectrometry technology that was initially developed in collabora
-
Astrotech Reports First Quarter of Fiscal Year 2020 Financial Results
11/13/2019
Astrotech Corporation reported its financial results for the first quarter of fiscal year 2020, which ended September 30, 2019.